clinical trial retatrutide Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 trials, is being sold openly across the internet and prescribed by licensed physicians online and Eli Lilly infiltrates anti-obesity market

In addition to GLP-1s, the startup offers weight-management medications including metformin

Microdosing GLP-1 (contains semaglutide): $250/month Microdosing GIP (contains tirzepatide): $340/month All dosages for each medication are the same cost with our flat fee pricing

CAS Number 2381089-83-2 Molecular Formula C221H342N46O68 Molecular Weight 4731.4 g/mol Half-Life ~6 days (research reports) Sources & References Triple-Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial Jastreboff AM, et al

& Drucker, D

NICE guidance supports the use of GLP-1 receptor agonists for type 2 diabetes (NG28) when certain criteria are met, typically after other treatments have been tried